CDK9 as modifier of the IGF pathway and methods of use
US8758994B2 · kind B2 · utility
0Cited by
0References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 20, 2005 |
| Grant date | Jun 24, 2014 |
| Priority date | — |
| Expiry date | Nov 13, 2029 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10T436/143333
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Human CDK9 genes are identified as modulators of the IGF pathway, and thus are therapeutic targets for disorders associated with defective IGF function. Methods for identifying modulators of IGF, comprising screening for agents that modulate the activity of CDK9 are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.